Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 3/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712371 | 0.82 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL28528205 | 0.82 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL19358192 | 0.80 | KMT2A (0.59) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL20825600 | 0.80 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL9283053 | 0.80 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL21332462 | 0.80 | KMT2A (0.66) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL120274 | 0.79 | KMT2A (0.61) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL8621066 | 0.79 | KMT2A (0.54) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL13906651 | 0.79 | KMT2A (0.51) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL30238049 | 0.79 | KMT2A (0.64) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1330638-C | Substituted imidazolidine derivatives, their prepn., their use and pharmaceutical prepn. comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 2007-08-08 | — | — | CN | disclosed |
| US-6521654-B2 | For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-03 | — | — | US | disclosed |
| US-6331552-B1 | THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISORDERS, FOR EXAMPLE OF RHEUMATOID ARTHRITIS, OR OF ALLERGIC DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-18 | — | — | US | disclosed |
| CN-1225360-A | Substituted imidazolidine derivatives, their prepn., their use and pharmaceutical prepn. comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | VCAM1, ITGA1, ITGA4 | KMT2A 1038/4885EPHX2 988/4885CASP3 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.